Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

SCN1A – Myoclonic-Astatic Epilepsy

SCN1A has been implicated in a small number of sporadic myoclonic-astatic epilepsy (Doose syndrome) cases but overall evidence for a causal role is sparse. A de novo heterozygous missense variant c.3521C>G (p.Thr1174Ser) was reported in a single patient with MAE (PMID:15944908). However, analysis of 22 unrelated sporadic MAE cases failed to identify pathogenic SCN1A mutations, arguing against a frequent contribution to MAE (PMID:14642997). No familial segregation has been observed, and functional studies have not evaluated MAE-specific SCN1A variants directly, although SCN1A haploinsufficiency is established in related epilepsies. This conflicting dataset supports a Limited gene–disease association, with insufficient genetic and experimental evidence for routine diagnostic use. Further large-scale screening and functional characterization in MAE are required.

References

  • Epilepsy research • 2003 • Absence of mutations in major GEFS+ genes in myoclonic astatic epilepsy. PMID:14642997
  • Neuropediatrics • 2005 • SCN1A mutation analysis in myoclonic astatic epilepsy and severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures. PMID:15944908

Evidence Based Scoring (AI generated)

Gene–Disease Association

Limited

Single proband with de novo SCN1A missense variant; negative screening of 22 sporadic MAE cases; no segregation support

Genetic Evidence

Limited

Only one de novo variant reported in MAE; lack of family segregation and low case count

Functional Evidence

Limited

No direct functional studies on MAE-specific SCN1A variants; mechanism inferred from related epilepsies